Harpoon Therapeutics Inc. (HARP)
NASDAQ: HARP
· Real-Time Price · USD
23.01
0.02 (0.09%)
At close: Mar 08, 2024, 10:00 PM
Harpoon Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 4.45M | 20.22M | 8.58M | 4.09M | 13.62M | 8.3M | 5.91M | 4.33M | 4.48M | 5.84M | 9.01M |
Cost of Revenue | 236K | 568K | 1.1M | 910K | 706K | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 4.21M | 19.65M | 7.48M | 3.18M | 12.91M | 8.3M | 5.91M | 4.33M | 4.48M | 5.84M | 9.01M |
Operating Income | -12.14M | 2.49M | -10.77M | -18.71M | -11.89M | -17.41M | -20.31M | -21.54M | -16.68M | -16.77M | -61.77M |
Interest Income | 480K | 615K | 425K | 343K | 289K | 104K | 40K | 36K | 48K | 62K | 94K |
Pretax Income | -1.8M | 1.06M | -11.34M | -18.42M | -11.64M | -17.35M | -20.32M | -21.55M | -16.68M | -16.76M | -61.72M |
Net Income | -1.8M | 1.06M | -12.05M | -18.07M | -11.39M | -17.29M | -20.33M | -21.55M | -16.68M | -16.76M | -61.72M |
Selling & General & Admin | 4.26M | 3.8M | 4.18M | 3.85M | 4.53M | 5.06M | 5.4M | 5.2M | 4.19M | 4.33M | 4.6M |
Research & Development | 12.32M | 12.2M | 15.16M | 18.95M | 20.98M | 20.65M | 20.82M | 20.66M | 16.97M | 18.27M | 16.22M |
Other Expenses | 11.9M | -488K | -860K | -50K | -40K | -44K | -48K | -47K | -55K | -58K | -51K |
Operating Expenses | 16.59M | 16M | 19.35M | 22.8M | 25.51M | 25.71M | 26.22M | 25.87M | 21.16M | 22.61M | 20.82M |
Interest Expense | 2.05M | 1.56M | 138K | n/a | 289K | 104K | 40K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 16.59M | 16M | 19.35M | 22.8M | 25.51M | 25.71M | 26.22M | 25.87M | 21.16M | 22.61M | 20.82M |
Income Tax Expense | n/a | 1.07M | 711K | -345K | -249K | -60K | 8K | -36K | -48K | -62K | n/a |
Shares Outstanding (Basic) | 3.95M | 3.77M | 3.7M | 3.37M | 3.31M | 3.3M | 3.29M | 3.27M | 3.26M | 3.25M | 3.16M |
Shares Outstanding (Diluted) | 3.95M | 3.8M | 3.7M | 3.37M | 3.31M | 3.3M | 3.29M | 3.27M | 3.26M | 3.25M | 3.16M |
EPS (Basic) | -0.46 | 0.30 | -3.26 | -5.37 | -3.45 | -5.23 | -6.18 | -6.6 | -5.1 | -5.2 | -19.5 |
EPS (Diluted) | -0.46 | 0.30 | -3.26 | -5.37 | -3.45 | -5.23 | -6.18 | -6.6 | -5.1 | -5.2 | -19.5 |
EBITDA | 480K | 2.49M | -10.77M | -18.71M | -11.18M | -16.69M | -19.71M | -20.98M | -16.14M | -16.22M | -11.16M |
EBIT | -3.85M | 2.62M | -11.2M | -18.77M | -11.35M | -17.25M | -20.28M | -21.54M | -16.68M | -16.77M | n/a |
Depreciation & Amortization | 236K | 370K | 227K | 678K | 527K | 548K | 604K | 558K | 534K | 549K | 549K |